| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 15,139 @ USD 456.2 | USD 6,906,412 | The ETF bought 15139 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 456.2 compared to the previous average buy price of 421.965. This is 8.1% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 49,725 @ USD 124.29 | USD 6,180,320 | The ETF bought 49725 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 124.29 compared to the previous average buy price of 115.871. This is 7.3% higher than average price of previous purchases of GILD. |
| AZN - AstraZeneca PLC | BUY | 16,538 @ USD 91.36 | USD 1,510,912 | The ETF bought 16538 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 91.36 compared to the previous average buy price of 78.7875. This is 16.0% higher than average price of previous purchases of AZN. |
| AMGN - Amgen Inc | BUY | 2,742 @ USD 327.38 | USD 897,676 | The ETF bought 2742 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 327.38 compared to the previous average buy price of 299.477. This is 9.3% higher than average price of previous purchases of AMGN. |
| RNA - Avidity Biosciences Inc | BUY | 7,842 @ USD 72.34 | USD 567,290 | The ETF bought 7842 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.34 compared to the previous average buy price of 46.9429. This is 54.1% higher than average price of previous purchases of RNA. |
| PRAX - Praxis Precision Medicines Inc | BUY | 1,514 @ USD 272.92 | USD 413,201 | The ETF bought 1514 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 272.92 compared to the previous average buy price of 98.2598. This is 177.8% higher than average price of previous purchases of PRAX. |
| GMAB - Genmab AS | BUY | 9,627 @ USD 32.38 | USD 311,722 | The ETF bought 9627 new shares of GMAB (Genmab AS). The shares were bought for an average price of 32.38 compared to the previous average buy price of 25.5228. This is 26.9% higher than average price of previous purchases of GMAB. |
| SYRE - Spyre Therapeutics Inc. | BUY | 7,958 @ USD 33.4 | USD 265,797 | The ETF bought 7958 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 33.4 compared to the previous average buy price of 21.6111. This is 54.6% higher than average price of previous purchases of SYRE. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 3,374 @ USD 78.54 | USD 264,994 | The ETF bought 3374 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 78.54 compared to the previous average buy price of 52.0132. This is 51.0% higher than average price of previous purchases of APGE. |
| OCUL - Ocular Therapeutix Inc | BUY | 16,295 @ USD 12.56 | USD 204,665 | The ETF bought 16295 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 12.56 compared to the previous average buy price of 10.7426. This is 16.9% higher than average price of previous purchases of OCUL. |
| NRIX - Nurix Therapeutics Inc | BUY | 11,040 @ USD 18.52 | USD 204,461 | The ETF bought 11040 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 18.52 compared to the previous average buy price of 13.2326. This is 40.0% higher than average price of previous purchases of NRIX. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 4,737 @ USD 36.83 | USD 174,464 | The ETF bought 4737 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 36.83 compared to the previous average buy price of 24.5678. This is 49.9% higher than average price of previous purchases of MLYS. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 36,543 @ USD 4.26 | USD 155,673 | The ETF bought 36543 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.26 compared to the previous average buy price of 5.51461. This is -22.8% lower than average price of previous purchases of RXRX. |
| MNMD - Mind Medicine Inc | BUY | 11,148 @ USD 12.7 | USD 141,580 | The ETF bought 11148 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.7 compared to the previous average buy price of 9.5334. This is 33.2% higher than average price of previous purchases of MNMD. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 10,460 @ USD 12.02 | USD 125,729 | The ETF bought 10460 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 12.02 compared to the previous average buy price of 8.41455. This is 42.8% higher than average price of previous purchases of AMLX. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 1,794 @ USD 64.94 | USD 116,502 | The ETF bought 1794 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 64.94 compared to the previous average buy price of 27.9063. This is 132.7% higher than average price of previous purchases of GPCR. |
| TNGX - Tango Therapeutics Inc | BUY | 11,471 @ USD 8.52 | USD 97,733 | The ETF bought 11471 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 8.52 compared to the previous average buy price of 7.2819. This is 17.0% higher than average price of previous purchases of TNGX. |
| PGEN - Precigen Inc | BUY | 20,918 @ USD 4.32 | USD 90,366 | The ETF bought 20918 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.32 compared to the previous average buy price of 2.70172. This is 59.9% higher than average price of previous purchases of PGEN. |
| SVRA - Savara Inc | BUY | 14,272 @ USD 6.05 | USD 86,346 | The ETF bought 14272 new shares of SVRA (Savara Inc). The shares were bought for an average price of 6.05 compared to the previous average buy price of 3.7196. This is 62.7% higher than average price of previous purchases of SVRA. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 3,022 @ USD 27.93 | USD 84,404 | The ETF bought 3022 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 27.93 compared to the previous average buy price of 11.1658. This is 150.1% higher than average price of previous purchases of OLMA. |
| INVA - Innoviva Inc | BUY | 3,523 @ USD 19.99 | USD 70,425 | The ETF bought 3523 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.99 compared to the previous average buy price of 19.6062. This is 2.0% higher than average price of previous purchases of INVA. |
| QURE - Uniqure NV | BUY | 2,556 @ USD 23.99 | USD 61,318 | The ETF bought 2556 new shares of QURE (Uniqure NV). The shares were bought for an average price of 23.99 compared to the previous average buy price of 23.4439. This is 2.3% higher than average price of previous purchases of QURE. |
| COGT - Cogent Biosciences Inc | BUY | 1,397 @ USD 39.55 | USD 55,251 | The ETF bought 1397 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 39.55 compared to the previous average buy price of 18.29. This is 116.2% higher than average price of previous purchases of COGT. |
| ALT - Altitude Group Plc | BUY | 9,473 @ USD 3.9 | USD 36,945 | The ETF bought 9473 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 3.9 compared to the previous average buy price of 5.14417. This is -24.2% lower than average price of previous purchases of ALT. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.02999 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.02999. The average price that ACIU shares were previous bought at was USD 2.56758. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 5,825 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.42 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.42. The average price that ALLO shares were previous bought at was USD 1.34689. The current market price is 5.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.53001 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.53001. The average price that ARCT shares were previous bought at was USD 12.4562. The current market price is -47.6% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 2,078 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.14001 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.14001. The average price that AVIR shares were previous bought at was USD 3.25167. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in AVIR has increased by USD 612 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 3.67 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 3.67. The average price that AVXL shares were previous bought at was USD 8.07409. The current market price is -54.5% lower than average price they were purchased at. The value of the holding in AVXL has fallen by USD 13,763 compared to the previous valuation of Anavex Life Sciences Corp |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 6.87001 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 6.87001. The average price that BCYC shares were previous bought at was USD 8.15555. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in BCYC has increased by USD 3,451 compared to the previous valuation of Bicycle Therapeutics Ltd however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 62.69 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 62.69. The average price that CYTK shares were previous bought at was USD 48.9512. The current market price is 28.1% higher than average price they were purchased at. The value of the holding in CYTK has increased by USD 43,181 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.34 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.34. The average price that EDIT shares were previous bought at was USD 2.61551. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in EDIT has fallen by USD 699 compared to the previous valuation of Editas Medicine Inc |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 8.68 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 8.68. The average price that FDMT shares were previous bought at was USD 7.76202. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in FDMT has fallen by USD 364 compared to the previous valuation of 4D Molecular Therapeutics Inc |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 91.09 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 91.09. The average price that GRAL shares were previous bought at was USD 63.9902. The current market price is 42.3% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 73,682 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.11 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.11. The average price that HUMA shares were previous bought at was USD 1.98857. The current market price is -44.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 36.01 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 36.01. The average price that IMCR shares were previous bought at was USD 34.3094. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in IMCR has increased by USD 3,279 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.48 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.48. The average price that IOVA shares were previous bought at was USD 2.3941. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in IOVA has increased by USD 5,152 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| IRON - Ironveld Plc | HOLD | 0 @ USD 80.04 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 80.04. The average price that IRON shares were previous bought at was USD 66.217. The current market price is 20.9% higher than average price they were purchased at. The value of the holding in IRON has fallen by USD 266,365 compared to the previous valuation of Ironveld Plc |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 33.33 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 33.33. The average price that LYEL shares were previous bought at was USD 8.48496. The current market price is 292.8% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 13,259 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 9.23 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 9.23. The average price that NTLA shares were previous bought at was USD 11.4968. The current market price is -19.7% lower than average price they were purchased at. The value of the holding in NTLA has increased by USD 27,600 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 103.8 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 103.8. The average price that NUVL shares were previous bought at was USD 88.7259. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 117,641 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 2.09 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 2.09. The average price that OABI shares were previous bought at was USD 1.88823. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in OABI has increased by USD 7,198 compared to the previous valuation of OmniAb Inc. however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 37.25 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 37.25. The average price that PAHC shares were previous bought at was USD 31.5119. The current market price is 18.2% higher than average price they were purchased at. The value of the holding in PAHC has fallen by USD 46,057 compared to the previous valuation of Phibro Animal Health Corporation |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.64. The average price that PRME shares were previous bought at was USD 4.34727. The current market price is -16.3% lower than average price they were purchased at. The value of the holding in PRME has increased by USD 5,081 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 9.21 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 9.21. The average price that PRTA shares were previous bought at was USD 9.45542. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in PRTA has fallen by USD 6,785 compared to the previous valuation of Prothena Corporation plc |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.23 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.23. The average price that RCKT shares were previous bought at was USD 4.6478. The current market price is -30.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.27 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.27. The average price that SIGA shares were previous bought at was USD 6.6331. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in SIGA has fallen by USD 2,047 compared to the previous valuation of SIGA Technologies Inc |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.04 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.04. The average price that SRPT shares were previous bought at was USD 30.0903. The current market price is -30.1% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 50,964 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 43.9 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 43.9. The average price that SRRK shares were previous bought at was USD 36.9163. The current market price is 18.9% higher than average price they were purchased at. The value of the holding in SRRK has increased by USD 68,442 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-19 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4. The average price that VYGR shares were previous bought at was USD 3.93356. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in VYGR has fallen by USD 4,501 compared to the previous valuation of Voyager Therapeutics Inc |
| OKUR - OKUR | SELL | -8,372 @ USD 3.01031 | USD -25,202 | The ETF sold 8372 shares of OKUR on 2025-12-19. The shares were previously bought for an average price of USD 5.56734. The OKUR shares were sold for -45.9% lower than average price of previous purchases. This resulted in an overall loss of USD 21,407 The average price that the ETF previously sold OKUR share for is USD 4.41663 which is higher than the selling price of USD 3.01031 on 2025-12-19. |
| SANA - Sana Biotechnology Inc | SELL | -9,430 @ USD 4.36 | USD -41,115 | The ETF sold 9430 shares of SANA on 2025-12-19. The shares were previously bought for an average price of USD 3.49243. The Sana Biotechnology Inc shares were sold for 24.8% higher than average price of previous purchases. This sale made a profit of USD 8,181 The average price that the ETF previously sold SANA share for is USD 2.55071 so the ETF has sold 9430 shares on 2025-12-19 at a higher price than the previous selling average. |
| VIR - Vir Biotechnology Inc | SELL | -7,341 @ USD 5.76 | USD -42,284 | The ETF sold 7341 shares of VIR on 2025-12-19. The shares were previously bought for an average price of USD 5.92884. The Vir Biotechnology Inc shares were sold for -2.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,239 The average price that the ETF previously sold VIR share for is USD 6.36001 which is higher than the selling price of USD 5.76 on 2025-12-19. |
| VIR - Vidrala S.A | SELL | -7,341 @ USD 5.76 | USD -42,284 | The ETF sold 7341 shares of VIR on 2025-12-19. The shares were previously bought for an average price of USD 5.92884. The Vidrala S.A shares were sold for -2.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,239 The average price that the ETF previously sold VIR share for is USD 6.36001 which is higher than the selling price of USD 5.76 on 2025-12-19. |
| GERN - Geron Corporation | SELL | -32,196 @ USD 1.33 | USD -42,821 | The ETF sold 32196 shares of GERN on 2025-12-19. The shares were previously bought for an average price of USD 1.43749. The Geron Corporation shares were sold for -7.5% lower than average price of previous purchases. This resulted in an overall loss of USD 3,461 The average price that the ETF previously sold GERN share for is USD 2.16635 which is higher than the selling price of USD 1.33 on 2025-12-19. |
| PACB - Pacific Biosciences of California | SELL | -23,628 @ USD 1.84 | USD -43,476 | The ETF sold 23628 shares of PACB on 2025-12-19. The shares were previously bought for an average price of USD 1.69829. The Pacific Biosciences of California shares were sold for 8.3% higher than average price of previous purchases. This sale made a profit of USD 3,348 The average price that the ETF previously sold PACB share for is USD 1.46917 so the ETF has sold 23628 shares on 2025-12-19 at a higher price than the previous selling average. |
| JANX - Janux Therapeutics Inc | SELL | -3,197 @ USD 13.79 | USD -44,087 | The ETF sold 3197 shares of JANX on 2025-12-19. The shares were previously bought for an average price of USD 26.2528. The Janux Therapeutics Inc shares were sold for -47.5% lower than average price of previous purchases. This resulted in an overall loss of USD 39,844 The average price that the ETF previously sold JANX share for is USD 35.2838 which is higher than the selling price of USD 13.79 on 2025-12-19. |
| ORIC - Oric Pharmaceuticals Inc | SELL | -5,484 @ USD 8.04 | USD -44,091 | The ETF sold 5484 shares of ORIC on 2025-12-19. The shares were previously bought for an average price of USD 10.6475. The Oric Pharmaceuticals Inc shares were sold for -24.5% lower than average price of previous purchases. This resulted in an overall loss of USD 14,300 The average price that the ETF previously sold ORIC share for is USD 8.29207 which is higher than the selling price of USD 8.04 on 2025-12-19. |
| TRDA - Entrada Therapeutics Inc | SELL | -4,018 @ USD 10.98 | USD -44,118 | The ETF sold 4018 shares of TRDA on 2025-12-19. The shares were previously bought for an average price of USD 8.23347. The Entrada Therapeutics Inc shares were sold for 33.4% higher than average price of previous purchases. This sale made a profit of USD 11,036 The average price that the ETF previously sold TRDA share for is USD 8.6758 so the ETF has sold 4018 shares on 2025-12-19 at a higher price than the previous selling average. |
| IBRX - Immunitybio Inc | SELL | -21,362 @ USD 2.08 | USD -44,433 | The ETF sold 21362 shares of IBRX on 2025-12-19. The shares were previously bought for an average price of USD 2.6304. The Immunitybio Inc shares were sold for -20.9% lower than average price of previous purchases. This resulted in an overall loss of USD 11,758 The average price that the ETF previously sold IBRX share for is USD 2.9485 which is higher than the selling price of USD 2.08 on 2025-12-19. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -6,610 @ USD 6.75001 | USD -44,618 | The ETF sold 6610 shares of VNDA on 2025-12-19. The shares were previously bought for an average price of USD 4.93606. The Vanda Pharmaceuticals Inc shares were sold for 36.7% higher than average price of previous purchases. This sale made a profit of USD 11,990 The average price that the ETF previously sold VNDA share for is USD 4.84569 so the ETF has sold 6610 shares on 2025-12-19 at a higher price than the previous selling average. |
| MGTX - MeiraGTx Holdings PLC | SELL | -5,558 @ USD 8.03 | USD -44,631 | The ETF sold 5558 shares of MGTX on 2025-12-19. The shares were previously bought for an average price of USD 7.4402. The MeiraGTx Holdings PLC shares were sold for 7.9% higher than average price of previous purchases. This sale made a profit of USD 3,278 The average price that the ETF previously sold MGTX share for is USD 7.01152 so the ETF has sold 5558 shares on 2025-12-19 at a higher price than the previous selling average. |
| CSTL - Castle Biosciences Inc | SELL | -1,137 @ USD 39.44 | USD -44,843 | The ETF sold 1137 shares of CSTL on 2025-12-19. The shares were previously bought for an average price of USD 26.271. The Castle Biosciences Inc shares were sold for 50.1% higher than average price of previous purchases. This sale made a profit of USD 14,973 The average price that the ETF previously sold CSTL share for is USD 24.5399 so the ETF has sold 1137 shares on 2025-12-19 at a higher price than the previous selling average. |
| XNCR - Xencor Inc | SELL | -2,886 @ USD 15.55 | USD -44,877 | The ETF sold 2886 shares of XNCR on 2025-12-19. The shares were previously bought for an average price of USD 12.5279. The Xencor Inc shares were sold for 24.1% higher than average price of previous purchases. This sale made a profit of USD 8,722 The average price that the ETF previously sold XNCR share for is USD 13.0743 so the ETF has sold 2886 shares on 2025-12-19 at a higher price than the previous selling average. |
| ABUS - Arbutus Biopharma Corp | SELL | -10,180 @ USD 4.43 | USD -45,097 | The ETF sold 10180 shares of ABUS on 2025-12-19. The shares were previously bought for an average price of USD 3.83964. The Arbutus Biopharma Corp shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of USD 6,010 The average price that the ETF previously sold ABUS share for is USD 3.43548 so the ETF has sold 10180 shares on 2025-12-19 at a higher price than the previous selling average. |
| CGEM - Cullinan Oncology LLC | SELL | -4,701 @ USD 9.68001 | USD -45,506 | The ETF sold 4701 shares of CGEM on 2025-12-19. The shares were previously bought for an average price of USD 8.57694. The Cullinan Oncology LLC shares were sold for 12.9% higher than average price of previous purchases. This sale made a profit of USD 5,186 The average price that the ETF previously sold CGEM share for is USD 10.0747 which is higher than the selling price of USD 9.68001 on 2025-12-19. |
| NVAX - Novavax Inc | SELL | -6,903 @ USD 6.66 | USD -45,974 | The ETF sold 6903 shares of NVAX on 2025-12-19. The shares were previously bought for an average price of USD 7.2023. The Novavax Inc shares were sold for -7.5% lower than average price of previous purchases. This resulted in an overall loss of USD 3,743 The average price that the ETF previously sold NVAX share for is USD 7.58522 which is higher than the selling price of USD 6.66 on 2025-12-19. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -6,903 @ USD 6.66 | USD -45,974 | The ETF sold 6903 shares of NVAX on 2025-12-19. The shares were previously bought for an average price of USD 7.2023. The Hana Microelectronics Public Company Limited shares were sold for -7.5% lower than average price of previous purchases. This resulted in an overall loss of USD 3,743 The average price that the ETF previously sold NVAX share for is USD 7.58522 which is higher than the selling price of USD 6.66 on 2025-12-19. |
| GRFS - Grifols SA ADR | SELL | -5,103 @ USD 9.02 | USD -46,029 | The ETF sold 5103 shares of GRFS on 2025-12-19. The shares were previously bought for an average price of USD 9.21387. The Grifols SA ADR shares were sold for -2.1% lower than average price of previous purchases. This resulted in an overall loss of USD 989 The average price that the ETF previously sold GRFS share for is USD 8.48253 so the ETF has sold 5103 shares on 2025-12-19 at a higher price than the previous selling average. |
| REPL - Replimune Group Inc | SELL | -4,666 @ USD 9.88 | USD -46,100 | The ETF sold 4666 shares of REPL on 2025-12-19. The shares were previously bought for an average price of USD 9.15336. The Replimune Group Inc shares were sold for 7.9% higher than average price of previous purchases. This sale made a profit of USD 3,391 The average price that the ETF previously sold REPL share for is USD 9.938 which is higher than the selling price of USD 9.88 on 2025-12-19. |
| GLPG - Galapagos NV ADR | SELL | -1,430 @ USD 32.36 | USD -46,275 | The ETF sold 1430 shares of GLPG on 2025-12-19. The shares were previously bought for an average price of USD 29.7426. The Galapagos NV ADR shares were sold for 8.8% higher than average price of previous purchases. This sale made a profit of USD 3,743 The average price that the ETF previously sold GLPG share for is USD 27.3811 so the ETF has sold 1430 shares on 2025-12-19 at a higher price than the previous selling average. |
| GLPG - Galapagos N.V. | SELL | -1,430 @ USD 32.36 | USD -46,275 | The ETF sold 1430 shares of GLPG on 2025-12-19. The shares were previously bought for an average price of USD 29.7426. The Galapagos N.V. shares were sold for 8.8% higher than average price of previous purchases. This sale made a profit of USD 3,743 The average price that the ETF previously sold GLPG share for is USD 27.3811 so the ETF has sold 1430 shares on 2025-12-19 at a higher price than the previous selling average. |
| STOK - Stoke Therapeutics Inc | SELL | -1,454 @ USD 31.96 | USD -46,470 | The ETF sold 1454 shares of STOK on 2025-12-19. The shares were previously bought for an average price of USD 19.6492. The Stoke Therapeutics Inc shares were sold for 62.7% higher than average price of previous purchases. This sale made a profit of USD 17,900 The average price that the ETF previously sold STOK share for is USD 13.936 so the ETF has sold 1454 shares on 2025-12-19 at a higher price than the previous selling average. |
| EOLS - Evolus Inc | SELL | -6,619 @ USD 7.07 | USD -46,796 | The ETF sold 6619 shares of EOLS on 2025-12-19. The shares were previously bought for an average price of USD 8.56985. The Evolus Inc shares were sold for -17.5% lower than average price of previous purchases. This resulted in an overall loss of USD 9,928 The average price that the ETF previously sold EOLS share for is USD 10.5941 which is higher than the selling price of USD 7.07 on 2025-12-19. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -1,087 @ USD 43.19 | USD -46,948 | The ETF sold 1087 shares of KNSA on 2025-12-19. The shares were previously bought for an average price of USD 32.8049. The Kiniksa Pharmaceuticals Ltd shares were sold for 31.7% higher than average price of previous purchases. This sale made a profit of USD 11,289 The average price that the ETF previously sold KNSA share for is USD 24.7165 so the ETF has sold 1087 shares on 2025-12-19 at a higher price than the previous selling average. |
| AUTL - Autolus Therapeutics Ltd | SELL | -28,894 @ USD 1.63 | USD -47,097 | The ETF sold 28894 shares of AUTL on 2025-12-19. The shares were previously bought for an average price of USD 1.74199. The Autolus Therapeutics Ltd shares were sold for -6.4% lower than average price of previous purchases. This resulted in an overall loss of USD 3,236 The average price that the ETF previously sold AUTL share for is USD 2.05344 which is higher than the selling price of USD 1.63 on 2025-12-19. |
| CGON - CG Oncology, Inc. Common stock | SELL | -1,207 @ USD 39.03 | USD -47,109 | The ETF sold 1207 shares of CGON on 2025-12-19. The shares were previously bought for an average price of USD 33.0567. The CG Oncology, Inc. Common stock shares were sold for 18.1% higher than average price of previous purchases. This sale made a profit of USD 7,210 The average price that the ETF previously sold CGON share for is USD 29.1827 so the ETF has sold 1207 shares on 2025-12-19 at a higher price than the previous selling average. |
| TBPH - Theravance Biopharma Inc | SELL | -2,517 @ USD 18.79 | USD -47,294 | The ETF sold 2517 shares of TBPH on 2025-12-19. The shares were previously bought for an average price of USD 13.5517. The Theravance Biopharma Inc shares were sold for 38.7% higher than average price of previous purchases. This sale made a profit of USD 13,185 The average price that the ETF previously sold TBPH share for is USD 11.542 so the ETF has sold 2517 shares on 2025-12-19 at a higher price than the previous selling average. |
| ELVN - Enliven Therapeutics Inc. | SELL | -2,814 @ USD 16.87 | USD -47,472 | The ETF sold 2814 shares of ELVN on 2025-12-19. The shares were previously bought for an average price of USD 20.5559. The Enliven Therapeutics Inc. shares were sold for -17.9% lower than average price of previous purchases. This resulted in an overall loss of USD 10,372 The average price that the ETF previously sold ELVN share for is USD 21.0307 which is higher than the selling price of USD 16.87 on 2025-12-19. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -5,146 @ USD 9.24 | USD -47,549 | The ETF sold 5146 shares of DAWN on 2025-12-19. The shares were previously bought for an average price of USD 7.72272. The Day One Biopharmaceuticals Inc shares were sold for 19.6% higher than average price of previous purchases. This sale made a profit of USD 7,808 The average price that the ETF previously sold DAWN share for is USD 9.2589 which is higher than the selling price of USD 9.24 on 2025-12-19. |
| IRWD - Ironwood Pharmaceuticals Inc | SELL | -15,192 @ USD 3.13 | USD -47,551 | The ETF sold 15192 shares of IRWD on 2025-12-19. The shares were previously bought for an average price of USD 2.34928. The Ironwood Pharmaceuticals Inc shares were sold for 33.2% higher than average price of previous purchases. This sale made a profit of USD 11,861 The average price that the ETF previously sold IRWD share for is USD 2.71808 so the ETF has sold 15192 shares on 2025-12-19 at a higher price than the previous selling average. |
| ABCL - Abcellera Biologics Inc | SELL | -13,455 @ USD 3.6 | USD -48,438 | The ETF sold 13455 shares of ABCL on 2025-12-19. The shares were previously bought for an average price of USD 3.83934. The Abcellera Biologics Inc shares were sold for -6.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,220 The average price that the ETF previously sold ABCL share for is USD 3.19815 so the ETF has sold 13455 shares on 2025-12-19 at a higher price than the previous selling average. |
| ARDX - Ardelyx Inc | SELL | -8,627 @ USD 5.68 | USD -49,001 | The ETF sold 8627 shares of ARDX on 2025-12-19. The shares were previously bought for an average price of USD 4.92786. The Ardelyx Inc shares were sold for 15.3% higher than average price of previous purchases. This sale made a profit of USD 6,489 The average price that the ETF previously sold ARDX share for is USD 5.24748 so the ETF has sold 8627 shares on 2025-12-19 at a higher price than the previous selling average. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -14,350 @ USD 3.43 | USD -49,221 | The ETF sold 14350 shares of MRVI on 2025-12-19. The shares were previously bought for an average price of USD 2.94024. The Maravai Lifesciences Holdings Inc shares were sold for 16.7% higher than average price of previous purchases. This sale made a profit of USD 7,028 The average price that the ETF previously sold MRVI share for is USD 3.69424 which is higher than the selling price of USD 3.43 on 2025-12-19. |
| FTRE - Fortrea Holdings Inc. | SELL | -2,785 @ USD 17.74 | USD -49,406 | The ETF sold 2785 shares of FTRE on 2025-12-19. The shares were previously bought for an average price of USD 8.4198. The Fortrea Holdings Inc. shares were sold for 110.7% higher than average price of previous purchases. This sale made a profit of USD 25,957 The average price that the ETF previously sold FTRE share for is USD 12.89 so the ETF has sold 2785 shares on 2025-12-19 at a higher price than the previous selling average. |
| RGNX - Regenxbio Inc | SELL | -3,516 @ USD 14.59 | USD -51,298 | The ETF sold 3516 shares of RGNX on 2025-12-19. The shares were previously bought for an average price of USD 10.0406. The Regenxbio Inc shares were sold for 45.3% higher than average price of previous purchases. This sale made a profit of USD 15,996 The average price that the ETF previously sold RGNX share for is USD 8.12614 so the ETF has sold 3516 shares on 2025-12-19 at a higher price than the previous selling average. |
| DVAX - Dynavax Technologies Corporation | SELL | -4,739 @ USD 10.86 | USD -51,466 | The ETF sold 4739 shares of DVAX on 2025-12-19. The shares were previously bought for an average price of USD 10.6546. The Dynavax Technologies Corporation shares were sold for 1.9% higher than average price of previous purchases. This sale made a profit of USD 973 The average price that the ETF previously sold DVAX share for is USD 11.8484 which is higher than the selling price of USD 10.86 on 2025-12-19. |
| XERS - Xeris Pharmaceuticals Inc | SELL | -7,201 @ USD 7.34 | USD -52,855 | The ETF sold 7201 shares of XERS on 2025-12-19. The shares were previously bought for an average price of USD 6.22689. The Xeris Pharmaceuticals Inc shares were sold for 17.9% higher than average price of previous purchases. This sale made a profit of USD 8,016 The average price that the ETF previously sold XERS share for is USD 4.90815 so the ETF has sold 7201 shares on 2025-12-19 at a higher price than the previous selling average. |
| RLAY - Relay Therapeutics Inc | SELL | -6,569 @ USD 8.4 | USD -55,180 | The ETF sold 6569 shares of RLAY on 2025-12-19. The shares were previously bought for an average price of USD 4.90988. The Relay Therapeutics Inc shares were sold for 71.1% higher than average price of previous purchases. This sale made a profit of USD 22,927 The average price that the ETF previously sold RLAY share for is USD 4.2362 so the ETF has sold 6569 shares on 2025-12-19 at a higher price than the previous selling average. |
| NVCR - Novocure Ltd | SELL | -4,457 @ USD 12.84 | USD -57,228 | The ETF sold 4457 shares of NVCR on 2025-12-19. The shares were previously bought for an average price of USD 15.3912. The Novocure Ltd shares were sold for -16.6% lower than average price of previous purchases. This resulted in an overall loss of USD 11,371 The average price that the ETF previously sold NVCR share for is USD 19.2839 which is higher than the selling price of USD 12.84 on 2025-12-19. |
| TSHA - Taysha Gene Therapies Inc | SELL | -10,639 @ USD 5.49 | USD -58,408 | The ETF sold 10639 shares of TSHA on 2025-12-19. The shares were previously bought for an average price of USD 3.26801. The Taysha Gene Therapies Inc shares were sold for 68.0% higher than average price of previous purchases. This sale made a profit of USD 23,640 The average price that the ETF previously sold TSHA share for is USD 2.28985 so the ETF has sold 10639 shares on 2025-12-19 at a higher price than the previous selling average. |
| COLL - Collegium Pharmaceutical Inc | SELL | -1,200 @ USD 48.88 | USD -58,656 | The ETF sold 1200 shares of COLL on 2025-12-19. The shares were previously bought for an average price of USD 35.6563. The Collegium Pharmaceutical Inc shares were sold for 37.1% higher than average price of previous purchases. This sale made a profit of USD 15,868 The average price that the ETF previously sold COLL share for is USD 31.7378 so the ETF has sold 1200 shares on 2025-12-19 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -6,094 @ USD 9.84001 | USD -59,965 | The ETF sold 6094 shares of KURA on 2025-12-19. The shares were previously bought for an average price of USD 8.28389. The Kura Oncology Inc shares were sold for 18.8% higher than average price of previous purchases. This sale made a profit of USD 9,483 The average price that the ETF previously sold KURA share for is USD 8.95229 so the ETF has sold 6094 shares on 2025-12-19 at a higher price than the previous selling average. |
| AMPH - Amphastar P | SELL | -2,258 @ USD 26.6 | USD -60,063 | The ETF sold 2258 shares of AMPH on 2025-12-19. The shares were previously bought for an average price of USD 25.8292. The Amphastar P shares were sold for 3.0% higher than average price of previous purchases. This sale made a profit of USD 1,740 The average price that the ETF previously sold AMPH share for is USD 31.2037 which is higher than the selling price of USD 26.6 on 2025-12-19. |
| URGN - UroGen Pharma Ltd | SELL | -2,726 @ USD 22.8 | USD -62,153 | The ETF sold 2726 shares of URGN on 2025-12-19. The shares were previously bought for an average price of USD 17.0229. The UroGen Pharma Ltd shares were sold for 33.9% higher than average price of previous purchases. This sale made a profit of USD 15,748 The average price that the ETF previously sold URGN share for is USD 13.4662 so the ETF has sold 2726 shares on 2025-12-19 at a higher price than the previous selling average. |
| WVE - Wave Life Sciences Ltd | SELL | -3,960 @ USD 15.98 | USD -63,281 | The ETF sold 3960 shares of WVE on 2025-12-19. The shares were previously bought for an average price of USD 8.32371. The Wave Life Sciences Ltd shares were sold for 92.0% higher than average price of previous purchases. This sale made a profit of USD 30,319 The average price that the ETF previously sold WVE share for is USD 9.08369 so the ETF has sold 3960 shares on 2025-12-19 at a higher price than the previous selling average. |
| ANAB - AnaptysBio Inc | SELL | -1,336 @ USD 49.08 | USD -65,571 | The ETF sold 1336 shares of ANAB on 2025-12-19. The shares were previously bought for an average price of USD 28.5512. The AnaptysBio Inc shares were sold for 71.9% higher than average price of previous purchases. This sale made a profit of USD 27,426 The average price that the ETF previously sold ANAB share for is USD 20.2569 so the ETF has sold 1336 shares on 2025-12-19 at a higher price than the previous selling average. |
| KALV - Kalvista Pharmaceuticals Inc | SELL | -4,322 @ USD 15.23 | USD -65,824 | The ETF sold 4322 shares of KALV on 2025-12-19. The shares were previously bought for an average price of USD 13.5733. The Kalvista Pharmaceuticals Inc shares were sold for 12.2% higher than average price of previous purchases. This sale made a profit of USD 7,160 The average price that the ETF previously sold KALV share for is USD 12.0811 so the ETF has sold 4322 shares on 2025-12-19 at a higher price than the previous selling average. |
| TXG - 10X Genomics Inc | SELL | -4,124 @ USD 16.05 | USD -66,190 | The ETF sold 4124 shares of TXG on 2025-12-19. The shares were previously bought for an average price of USD 13.611. The 10X Genomics Inc shares were sold for 17.9% higher than average price of previous purchases. This sale made a profit of USD 10,058 The average price that the ETF previously sold TXG share for is USD 11.2884 so the ETF has sold 4124 shares on 2025-12-19 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -4,124 @ USD 16.05 | USD -66,190 | The ETF sold 4124 shares of TXG on 2025-12-19. The shares were previously bought for an average price of USD 13.611. The Terex Corporation shares were sold for 17.9% higher than average price of previous purchases. This sale made a profit of USD 10,058 The average price that the ETF previously sold TXG share for is USD 11.2884 so the ETF has sold 4124 shares on 2025-12-19 at a higher price than the previous selling average. |
| PHAT - Phathom Pharmaceuticals Inc | SELL | -3,848 @ USD 17.53 | USD -67,455 | The ETF sold 3848 shares of PHAT on 2025-12-19. The shares were previously bought for an average price of USD 10.5456. The Phathom Pharmaceuticals Inc shares were sold for 66.2% higher than average price of previous purchases. This sale made a profit of USD 26,876 The average price that the ETF previously sold PHAT share for is USD 8.13175 so the ETF has sold 3848 shares on 2025-12-19 at a higher price than the previous selling average. |
| FATE - Fate Therapeutics Inc | SELL | -67,539 @ USD 1.05 | USD -70,916 | The ETF sold 67539 shares of FATE on 2025-12-19. The shares were previously bought for an average price of USD 1.1465. The Fate Therapeutics Inc shares were sold for -8.4% lower than average price of previous purchases. This resulted in an overall loss of USD 6,518 The average price that the ETF previously sold FATE share for is USD 1.02881 so the ETF has sold 67539 shares on 2025-12-19 at a higher price than the previous selling average. |
| ERAS - Erasca Inc | SELL | -21,122 @ USD 3.45 | USD -72,871 | The ETF sold 21122 shares of ERAS on 2025-12-19. The shares were previously bought for an average price of USD 2.02691. The Erasca Inc shares were sold for 70.2% higher than average price of previous purchases. This sale made a profit of USD 30,059 The average price that the ETF previously sold ERAS share for is USD 2.08517 so the ETF has sold 21122 shares on 2025-12-19 at a higher price than the previous selling average. |
| ANIP - ANI Pharmaceuticals Inc | SELL | -917 @ USD 82.85 | USD -75,973 | The ETF sold 917 shares of ANIP on 2025-12-19. The shares were previously bought for an average price of USD 74.884. The ANI Pharmaceuticals Inc shares were sold for 10.6% higher than average price of previous purchases. This sale made a profit of USD 7,305 The average price that the ETF previously sold ANIP share for is USD 68.9234 so the ETF has sold 917 shares on 2025-12-19 at a higher price than the previous selling average. |
| SPRY - Silverback Therapeutics Inc | SELL | -7,669 @ USD 10.49 | USD -80,448 | The ETF sold 7669 shares of SPRY on 2025-12-19. The shares were previously bought for an average price of USD 12.4193. The Silverback Therapeutics Inc shares were sold for -15.5% lower than average price of previous purchases. This resulted in an overall loss of USD 14,796 The average price that the ETF previously sold SPRY share for is USD 11.9587 which is higher than the selling price of USD 10.49 on 2025-12-19. |
| PCRX - Pacira BioSciences, Inc. | SELL | -3,137 @ USD 26.35 | USD -82,660 | The ETF sold 3137 shares of PCRX on 2025-12-19. The shares were previously bought for an average price of USD 23.8626. The Pacira BioSciences, Inc. shares were sold for 10.4% higher than average price of previous purchases. This sale made a profit of USD 7,803 The average price that the ETF previously sold PCRX share for is USD 22.1765 so the ETF has sold 3137 shares on 2025-12-19 at a higher price than the previous selling average. |
| LEGN - Legend Biotech Corp | SELL | -3,908 @ USD 21.92 | USD -85,663 | The ETF sold 3908 shares of LEGN on 2025-12-19. The shares were previously bought for an average price of USD 32.7402. The Legend Biotech Corp shares were sold for -33.0% lower than average price of previous purchases. This resulted in an overall loss of USD 42,285 The average price that the ETF previously sold LEGN share for is USD 33.9326 which is higher than the selling price of USD 21.92 on 2025-12-19. |
| AGIO - Agios Pharm | SELL | -3,801 @ USD 24.46 | USD -92,972 | The ETF sold 3801 shares of AGIO on 2025-12-19. The shares were previously bought for an average price of USD 33.9293. The Agios Pharm shares were sold for -27.9% lower than average price of previous purchases. This resulted in an overall loss of USD 35,993 The average price that the ETF previously sold AGIO share for is USD 35.3579 which is higher than the selling price of USD 24.46 on 2025-12-19. |
| ACLX - Arcellx Inc | SELL | -1,631 @ USD 63.96 | USD -104,319 | The ETF sold 1631 shares of ACLX on 2025-12-19. The shares were previously bought for an average price of USD 72.202. The Arcellx Inc shares were sold for -11.4% lower than average price of previous purchases. This resulted in an overall loss of USD 13,443 The average price that the ETF previously sold ACLX share for is USD 74.927 which is higher than the selling price of USD 63.96 on 2025-12-19. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -14,103 @ USD 7.41 | USD -104,503 | The ETF sold 14103 shares of BCRX on 2025-12-19. The shares were previously bought for an average price of USD 8.03142. The BioCryst Pharmaceuticals Inc shares were sold for -7.7% lower than average price of previous purchases. This resulted in an overall loss of USD 8,764 The average price that the ETF previously sold BCRX share for is USD 7.53909 which is higher than the selling price of USD 7.41 on 2025-12-19. |
| SNDX - Syndax Pharmaceuticals Inc | SELL | -5,207 @ USD 20.77 | USD -108,149 | The ETF sold 5207 shares of SNDX on 2025-12-19. The shares were previously bought for an average price of USD 14.0596. The Syndax Pharmaceuticals Inc shares were sold for 47.7% higher than average price of previous purchases. This sale made a profit of USD 34,941 The average price that the ETF previously sold SNDX share for is USD 13.7298 so the ETF has sold 5207 shares on 2025-12-19 at a higher price than the previous selling average. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -2,175 @ USD 51.48 | USD -111,969 | The ETF sold 2175 shares of SUPN on 2025-12-19. The shares were previously bought for an average price of USD 39.4199. The Supernus Pharmaceuticals Inc shares were sold for 30.6% higher than average price of previous purchases. This sale made a profit of USD 26,231 The average price that the ETF previously sold SUPN share for is USD 37.6191 so the ETF has sold 2175 shares on 2025-12-19 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -3,613 @ USD 32.51 | USD -117,459 | The ETF sold 3613 shares of TWST on 2025-12-19. The shares were previously bought for an average price of USD 34.6802. The Twist Bioscience Corp shares were sold for -6.3% lower than average price of previous purchases. This resulted in an overall loss of USD 7,841 The average price that the ETF previously sold TWST share for is USD 37.9971 which is higher than the selling price of USD 32.51 on 2025-12-19. |
| MNKD - MannKind Corp | SELL | -20,202 @ USD 5.84 | USD -117,980 | The ETF sold 20202 shares of MNKD on 2025-12-19. The shares were previously bought for an average price of USD 4.95458. The MannKind Corp shares were sold for 17.9% higher than average price of previous purchases. This sale made a profit of USD 17,887 The average price that the ETF previously sold MNKD share for is USD 5.56101 so the ETF has sold 20202 shares on 2025-12-19 at a higher price than the previous selling average. |
| CRSP - Crispr Therapeutics AG | SELL | -2,117 @ USD 55.86 | USD -118,256 | The ETF sold 2117 shares of CRSP on 2025-12-19. The shares were previously bought for an average price of USD 53.3058. The Crispr Therapeutics AG shares were sold for 4.8% higher than average price of previous purchases. This sale made a profit of USD 5,407 The average price that the ETF previously sold CRSP share for is USD 44.1411 so the ETF has sold 2117 shares on 2025-12-19 at a higher price than the previous selling average. |
| HROW - Harrow Health Inc | SELL | -2,602 @ USD 46.4 | USD -120,733 | The ETF sold 2602 shares of HROW on 2025-12-19. The shares were previously bought for an average price of USD 37.118. The Harrow Health Inc shares were sold for 25.0% higher than average price of previous purchases. This sale made a profit of USD 24,152 The average price that the ETF previously sold HROW share for is USD 33.9315 so the ETF has sold 2602 shares on 2025-12-19 at a higher price than the previous selling average. |
| VCEL - Vericel Corp Ord | SELL | -3,405 @ USD 36.05 | USD -122,750 | The ETF sold 3405 shares of VCEL on 2025-12-19. The shares were previously bought for an average price of USD 39.9007. The Vericel Corp Ord shares were sold for -9.7% lower than average price of previous purchases. This resulted in an overall loss of USD 13,112 The average price that the ETF previously sold VCEL share for is USD 44.425 which is higher than the selling price of USD 36.05 on 2025-12-19. |
| TERN - Tern Plc | SELL | -3,239 @ USD 39.9 | USD -129,236 | The ETF sold 3239 shares of TERN on 2025-12-19. The shares were previously bought for an average price of USD 11.663. The Tern Plc shares were sold for 242.1% higher than average price of previous purchases. This sale made a profit of USD 91,460 The average price that the ETF previously sold TERN share for is USD 7.98155 so the ETF has sold 3239 shares on 2025-12-19 at a higher price than the previous selling average. |
| HRMY - Harmony Biosciences Holdings | SELL | -3,425 @ USD 37.81 | USD -129,499 | The ETF sold 3425 shares of HRMY on 2025-12-19. The shares were previously bought for an average price of USD 33.4492. The Harmony Biosciences Holdings shares were sold for 13.0% higher than average price of previous purchases. This sale made a profit of USD 14,936 The average price that the ETF previously sold HRMY share for is USD 32.3684 so the ETF has sold 3425 shares on 2025-12-19 at a higher price than the previous selling average. |
| CNTA - Centessa Pharmaceuticals PLC ADR | SELL | -5,306 @ USD 24.85 | USD -131,854 | The ETF sold 5306 shares of CNTA on 2025-12-19. The shares were previously bought for an average price of USD 19.5396. The Centessa Pharmaceuticals PLC ADR shares were sold for 27.2% higher than average price of previous purchases. This sale made a profit of USD 28,177 The average price that the ETF previously sold CNTA share for is USD 17.8207 so the ETF has sold 5306 shares on 2025-12-19 at a higher price than the previous selling average. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -4,889 @ USD 27.23 | USD -133,127 | The ETF sold 4889 shares of ZYME on 2025-12-19. The shares were previously bought for an average price of USD 17.3812. The Zymeworks Inc. Common Stock shares were sold for 56.7% higher than average price of previous purchases. This sale made a profit of USD 48,151 The average price that the ETF previously sold ZYME share for is USD 14.564 so the ETF has sold 4889 shares on 2025-12-19 at a higher price than the previous selling average. |
| ARQT - Arcutis Biotherapeutics Inc | SELL | -4,809 @ USD 28.01 | USD -134,700 | The ETF sold 4809 shares of ARQT on 2025-12-19. The shares were previously bought for an average price of USD 20.1616. The Arcutis Biotherapeutics Inc shares were sold for 38.9% higher than average price of previous purchases. This sale made a profit of USD 37,743 The average price that the ETF previously sold ARQT share for is USD 15.3478 so the ETF has sold 4809 shares on 2025-12-19 at a higher price than the previous selling average. |
| MIRM - Mirum Pharmaceuticals Inc | SELL | -1,763 @ USD 77.74 | USD -137,056 | The ETF sold 1763 shares of MIRM on 2025-12-19. The shares were previously bought for an average price of USD 59.3746. The Mirum Pharmaceuticals Inc shares were sold for 30.9% higher than average price of previous purchases. This sale made a profit of USD 32,378 The average price that the ETF previously sold MIRM share for is USD 50.5624 so the ETF has sold 1763 shares on 2025-12-19 at a higher price than the previous selling average. |
| DYN - Dyne Therapeutics Inc | SELL | -7,029 @ USD 19.85 | USD -139,526 | The ETF sold 7029 shares of DYN on 2025-12-19. The shares were previously bought for an average price of USD 14.4536. The Dyne Therapeutics Inc shares were sold for 37.3% higher than average price of previous purchases. This sale made a profit of USD 37,931 The average price that the ETF previously sold DYN share for is USD 17.3722 so the ETF has sold 7029 shares on 2025-12-19 at a higher price than the previous selling average. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | SELL | -7,029 @ USD 19.85 | USD -139,526 | The ETF sold 7029 shares of DYN on 2025-12-19. The shares were previously bought for an average price of USD 14.4536. The DYNAGREEN EN.PR.GR.H YC 1 shares were sold for 37.3% higher than average price of previous purchases. This sale made a profit of USD 37,931 The average price that the ETF previously sold DYN share for is USD 17.3722 so the ETF has sold 7029 shares on 2025-12-19 at a higher price than the previous selling average. |
| DNLI - Denali Therapeutics Inc | SELL | -8,352 @ USD 16.85 | USD -140,731 | The ETF sold 8352 shares of DNLI on 2025-12-19. The shares were previously bought for an average price of USD 16.1568. The Denali Therapeutics Inc shares were sold for 4.3% higher than average price of previous purchases. This sale made a profit of USD 5,790 The average price that the ETF previously sold DNLI share for is USD 17.2621 which is higher than the selling price of USD 16.85 on 2025-12-19. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -8,724 @ USD 16.18 | USD -141,154 | The ETF sold 8724 shares of AUPH on 2025-12-19. The shares were previously bought for an average price of USD 11.3392. The Aurinia Pharmaceuticals Inc shares were sold for 42.7% higher than average price of previous purchases. This sale made a profit of USD 42,231 The average price that the ETF previously sold AUPH share for is USD 9.84411 so the ETF has sold 8724 shares on 2025-12-19 at a higher price than the previous selling average. |
| ZLAB - Zai Lab Ltd | SELL | -7,893 @ USD 18.04 | USD -142,390 | The ETF sold 7893 shares of ZLAB on 2025-12-19. The shares were previously bought for an average price of USD 31.0921. The Zai Lab Ltd shares were sold for -42.0% lower than average price of previous purchases. This resulted in an overall loss of USD 103,020 The average price that the ETF previously sold ZLAB share for is USD 30.6599 which is higher than the selling price of USD 18.04 on 2025-12-19. |
| ARVN - Arvinas Inc | SELL | -12,212 @ USD 11.68 | USD -142,636 | The ETF sold 12212 shares of ARVN on 2025-12-19. The shares were previously bought for an average price of USD 9.94644. The Arvinas Inc shares were sold for 17.4% higher than average price of previous purchases. This sale made a profit of USD 21,170 The average price that the ETF previously sold ARVN share for is USD 12.3541 which is higher than the selling price of USD 11.68 on 2025-12-19. |
| EWTX - Edgewise Therapeutics Inc | SELL | -5,807 @ USD 25.55 | USD -148,369 | The ETF sold 5807 shares of EWTX on 2025-12-19. The shares were previously bought for an average price of USD 17.9438. The Edgewise Therapeutics Inc shares were sold for 42.4% higher than average price of previous purchases. This sale made a profit of USD 44,169 The average price that the ETF previously sold EWTX share for is USD 21.9136 so the ETF has sold 5807 shares on 2025-12-19 at a higher price than the previous selling average. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -8,738 @ USD 17 | USD -148,546 | The ETF sold 8738 shares of ADPT on 2025-12-19. The shares were previously bought for an average price of USD 13.4506. The Adaptive Biotechnologies Corp shares were sold for 26.4% higher than average price of previous purchases. This sale made a profit of USD 31,015 The average price that the ETF previously sold ADPT share for is USD 8.49422 so the ETF has sold 8738 shares on 2025-12-19 at a higher price than the previous selling average. |
| BEAM - Beam Therapeutics Inc | SELL | -5,855 @ USD 26.57 | USD -155,567 | The ETF sold 5855 shares of BEAM on 2025-12-19. The shares were previously bought for an average price of USD 21.9707. The Beam Therapeutics Inc shares were sold for 20.9% higher than average price of previous purchases. This sale made a profit of USD 26,929 The average price that the ETF previously sold BEAM share for is USD 22.8103 so the ETF has sold 5855 shares on 2025-12-19 at a higher price than the previous selling average. |
| APLS - Apellis Pharmaceuticals Inc | SELL | -6,479 @ USD 24.65 | USD -159,707 | The ETF sold 6479 shares of APLS on 2025-12-19. The shares were previously bought for an average price of USD 21.1068. The Apellis Pharmaceuticals Inc shares were sold for 16.8% higher than average price of previous purchases. This sale made a profit of USD 22,956 The average price that the ETF previously sold APLS share for is USD 24.96 which is higher than the selling price of USD 24.65 on 2025-12-19. |
| IDYA - Ideaya Biosciences Inc | SELL | -4,799 @ USD 33.55 | USD -161,006 | The ETF sold 4799 shares of IDYA on 2025-12-19. The shares were previously bought for an average price of USD 26.2583. The Ideaya Biosciences Inc shares were sold for 27.8% higher than average price of previous purchases. This sale made a profit of USD 34,993 The average price that the ETF previously sold IDYA share for is USD 23.5174 so the ETF has sold 4799 shares on 2025-12-19 at a higher price than the previous selling average. |
| TARS - Tarsus Pharmaceuticals Inc | SELL | -2,088 @ USD 81.4 | USD -169,963 | The ETF sold 2088 shares of TARS on 2025-12-19. The shares were previously bought for an average price of USD 56.6878. The Tarsus Pharmaceuticals Inc shares were sold for 43.6% higher than average price of previous purchases. This sale made a profit of USD 51,599 The average price that the ETF previously sold TARS share for is USD 52.269 so the ETF has sold 2088 shares on 2025-12-19 at a higher price than the previous selling average. |
| RARE - Ultragenyx | SELL | -5,079 @ USD 33.5 | USD -170,147 | The ETF sold 5079 shares of RARE on 2025-12-19. The shares were previously bought for an average price of USD 35.8581. The Ultragenyx shares were sold for -6.6% lower than average price of previous purchases. This resulted in an overall loss of USD 11,977 The average price that the ETF previously sold RARE share for is USD 37.0041 which is higher than the selling price of USD 33.5 on 2025-12-19. |
| RARE - WISETFWTMRARETFP | SELL | -5,079 @ USD 33.5 | USD -170,147 | The ETF sold 5079 shares of RARE on 2025-12-19. The shares were previously bought for an average price of USD 35.8581. The WISETFWTMRARETFP shares were sold for -6.6% lower than average price of previous purchases. This resulted in an overall loss of USD 11,977 The average price that the ETF previously sold RARE share for is USD 37.0041 which is higher than the selling price of USD 33.5 on 2025-12-19. |
| TVTX - Travere Therapeutics Inc | SELL | -4,933 @ USD 34.51 | USD -170,238 | The ETF sold 4933 shares of TVTX on 2025-12-19. The shares were previously bought for an average price of USD 24.1834. The Travere Therapeutics Inc shares were sold for 42.7% higher than average price of previous purchases. This sale made a profit of USD 50,941 The average price that the ETF previously sold TVTX share for is USD 20.5091 so the ETF has sold 4933 shares on 2025-12-19 at a higher price than the previous selling average. |
| VCYT - Veracyte Inc | SELL | -4,033 @ USD 42.92 | USD -173,096 | The ETF sold 4033 shares of VCYT on 2025-12-19. The shares were previously bought for an average price of USD 34.9468. The Veracyte Inc shares were sold for 22.8% higher than average price of previous purchases. This sale made a profit of USD 32,156 The average price that the ETF previously sold VCYT share for is USD 34.5412 so the ETF has sold 4033 shares on 2025-12-19 at a higher price than the previous selling average. |
| XENE - Xenon Pharmaceuticals Inc | SELL | -3,929 @ USD 44.1 | USD -173,269 | The ETF sold 3929 shares of XENE on 2025-12-19. The shares were previously bought for an average price of USD 37.5806. The Xenon Pharmaceuticals Inc shares were sold for 17.3% higher than average price of previous purchases. This sale made a profit of USD 25,615 The average price that the ETF previously sold XENE share for is USD 36.6457 so the ETF has sold 3929 shares on 2025-12-19 at a higher price than the previous selling average. |
| VERA - Vera Therapeutics Inc | SELL | -3,695 @ USD 51.22 | USD -189,258 | The ETF sold 3695 shares of VERA on 2025-12-19. The shares were previously bought for an average price of USD 30.2541. The Vera Therapeutics Inc shares were sold for 69.3% higher than average price of previous purchases. This sale made a profit of USD 77,469 The average price that the ETF previously sold VERA share for is USD 29.748 so the ETF has sold 3695 shares on 2025-12-19 at a higher price than the previous selling average. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -947 @ USD 200.33 | USD -189,713 | The ETF sold 947 shares of LGND on 2025-12-19. The shares were previously bought for an average price of USD 149.15. The Ligand Pharmaceuticals Incorporated shares were sold for 34.3% higher than average price of previous purchases. This sale made a profit of USD 48,467 The average price that the ETF previously sold LGND share for is USD 127.488 so the ETF has sold 947 shares on 2025-12-19 at a higher price than the previous selling average. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | SELL | -16,357 @ USD 12.57 | USD -205,607 | The ETF sold 16357 shares of AMRX on 2025-12-19. The shares were previously bought for an average price of USD 9.64518. The Amneal Pharmaceuticals, Inc. Class A Common Stock shares were sold for 30.3% higher than average price of previous purchases. This sale made a profit of USD 47,841 The average price that the ETF previously sold AMRX share for is USD 9.08797 so the ETF has sold 16357 shares on 2025-12-19 at a higher price than the previous selling average. |
| KROS - Keros Therapeutics Inc | SELL | -10,260 @ USD 20.26 | USD -207,868 | The ETF sold 10260 shares of KROS on 2025-12-19. The shares were previously bought for an average price of USD 15.8434. The Keros Therapeutics Inc shares were sold for 27.9% higher than average price of previous purchases. This sale made a profit of USD 45,314 The average price that the ETF previously sold KROS share for is USD 19.8845 so the ETF has sold 10260 shares on 2025-12-19 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -8,367 @ USD 27.16 | USD -227,248 | The ETF sold 8367 shares of ACAD on 2025-12-19. The shares were previously bought for an average price of USD 22.0973. The ACADIA Pharmaceuticals Inc shares were sold for 22.9% higher than average price of previous purchases. This sale made a profit of USD 42,360 The average price that the ETF previously sold ACAD share for is USD 18.6457 so the ETF has sold 8367 shares on 2025-12-19 at a higher price than the previous selling average. |
| IMVT - Immunovant Inc | SELL | -8,670 @ USD 26.68 | USD -231,316 | The ETF sold 8670 shares of IMVT on 2025-12-19. The shares were previously bought for an average price of USD 19.1832. The Immunovant Inc shares were sold for 39.1% higher than average price of previous purchases. This sale made a profit of USD 64,997 The average price that the ETF previously sold IMVT share for is USD 20.4185 so the ETF has sold 8670 shares on 2025-12-19 at a higher price than the previous selling average. |
| CRNX - Crinetics Pharmaceuticals Inc | SELL | -5,065 @ USD 48.01 | USD -243,171 | The ETF sold 5065 shares of CRNX on 2025-12-19. The shares were previously bought for an average price of USD 37.9409. The Crinetics Pharmaceuticals Inc shares were sold for 26.5% higher than average price of previous purchases. This sale made a profit of USD 51,000 The average price that the ETF previously sold CRNX share for is USD 37.3094 so the ETF has sold 5065 shares on 2025-12-19 at a higher price than the previous selling average. |
| ADMA - ADMA Biologics Inc | SELL | -12,733 @ USD 19.58 | USD -249,312 | The ETF sold 12733 shares of ADMA on 2025-12-19. The shares were previously bought for an average price of USD 17.8309. The ADMA Biologics Inc shares were sold for 9.8% higher than average price of previous purchases. This sale made a profit of USD 22,271 The average price that the ETF previously sold ADMA share for is USD 17.7895 so the ETF has sold 12733 shares on 2025-12-19 at a higher price than the previous selling average. |
| FOLD - Amicus Therapeutics Inc | SELL | -17,770 @ USD 14.18 | USD -251,979 | The ETF sold 17770 shares of FOLD on 2025-12-19. The shares were previously bought for an average price of USD 8.09081. The Amicus Therapeutics Inc shares were sold for 75.3% higher than average price of previous purchases. This sale made a profit of USD 108,205 The average price that the ETF previously sold FOLD share for is USD 8.6479 so the ETF has sold 17770 shares on 2025-12-19 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -9,396 @ USD 28.45 | USD -267,316 | The ETF sold 9396 shares of ALKS on 2025-12-19. The shares were previously bought for an average price of USD 30.05. The Alkermes Plc shares were sold for -5.3% lower than average price of previous purchases. This resulted in an overall loss of USD 15,034 The average price that the ETF previously sold ALKS share for is USD 29.3985 which is higher than the selling price of USD 28.45 on 2025-12-19. |
| PTGX - Protagonist Therapeutics Inc | SELL | -3,354 @ USD 86.05 | USD -288,612 | The ETF sold 3354 shares of PTGX on 2025-12-19. The shares were previously bought for an average price of USD 64.886. The Protagonist Therapeutics Inc shares were sold for 32.6% higher than average price of previous purchases. This sale made a profit of USD 70,984 The average price that the ETF previously sold PTGX share for is USD 52.0735 so the ETF has sold 3354 shares on 2025-12-19 at a higher price than the previous selling average. |
| PCVX - Vaxcyte Inc | SELL | -6,556 @ USD 46.42 | USD -304,330 | The ETF sold 6556 shares of PCVX on 2025-12-19. The shares were previously bought for an average price of USD 45.0066. The Vaxcyte Inc shares were sold for 3.1% higher than average price of previous purchases. This sale made a profit of USD 9,266 The average price that the ETF previously sold PCVX share for is USD 51.8206 which is higher than the selling price of USD 46.42 on 2025-12-19. |
| PTCT - PTC Therapeutics Inc | SELL | -3,877 @ USD 78.57 | USD -304,616 | The ETF sold 3877 shares of PTCT on 2025-12-19. The shares were previously bought for an average price of USD 61.273. The PTC Therapeutics Inc shares were sold for 28.2% higher than average price of previous purchases. This sale made a profit of USD 67,060 The average price that the ETF previously sold PTCT share for is USD 50.8224 so the ETF has sold 3877 shares on 2025-12-19 at a higher price than the previous selling average. |
| KYMR - Kymera Therapeutics Inc | SELL | -3,722 @ USD 83.99 | USD -312,611 | The ETF sold 3722 shares of KYMR on 2025-12-19. The shares were previously bought for an average price of USD 52.5563. The Kymera Therapeutics Inc shares were sold for 59.8% higher than average price of previous purchases. This sale made a profit of USD 116,996 The average price that the ETF previously sold KYMR share for is USD 41.1939 so the ETF has sold 3722 shares on 2025-12-19 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -2,317 @ USD 152.65 | USD -353,690 | The ETF sold 2317 shares of AXSM on 2025-12-19. The shares were previously bought for an average price of USD 123.568. The Axsome Therapeutics Inc shares were sold for 23.5% higher than average price of previous purchases. This sale made a profit of USD 67,383 The average price that the ETF previously sold AXSM share for is USD 106.587 so the ETF has sold 2317 shares on 2025-12-19 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -3,581 @ USD 99.74 | USD -357,169 | The ETF sold 3581 shares of GH on 2025-12-19. The shares were previously bought for an average price of USD 68.6525. The Guardant Health Inc shares were sold for 45.3% higher than average price of previous purchases. This sale made a profit of USD 111,324 The average price that the ETF previously sold GH share for is USD 45.7649 so the ETF has sold 3581 shares on 2025-12-19 at a higher price than the previous selling average. |
| KRYS - Krystal Biotech Inc | SELL | -1,553 @ USD 240.8 | USD -373,962 | The ETF sold 1553 shares of KRYS on 2025-12-19. The shares were previously bought for an average price of USD 177.51. The Krystal Biotech Inc shares were sold for 35.7% higher than average price of previous purchases. This sale made a profit of USD 98,289 The average price that the ETF previously sold KRYS share for is USD 170.107 so the ETF has sold 1553 shares on 2025-12-19 at a higher price than the previous selling average. |
| HALO - Halozyme Therapeutics Inc | SELL | -5,750 @ USD 67.35 | USD -387,262 | The ETF sold 5750 shares of HALO on 2025-12-19. The shares were previously bought for an average price of USD 61.4961. The Halozyme Therapeutics Inc shares were sold for 9.5% higher than average price of previous purchases. This sale made a profit of USD 33,660 The average price that the ETF previously sold HALO share for is USD 59.82 so the ETF has sold 5750 shares on 2025-12-19 at a higher price than the previous selling average. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -3,506 @ USD 112.14 | USD -393,163 | The ETF sold 3506 shares of RYTM on 2025-12-19. The shares were previously bought for an average price of USD 83.781. The Rhythm Pharmaceuticals Inc shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 99,427 The average price that the ETF previously sold RYTM share for is USD 66.7043 so the ETF has sold 3506 shares on 2025-12-19 at a higher price than the previous selling average. |
| RVMD - Revolution Medicines Inc | SELL | -6,131 @ USD 78.78 | USD -483,000 | The ETF sold 6131 shares of RVMD on 2025-12-19. The shares were previously bought for an average price of USD 50.1446. The Revolution Medicines Inc shares were sold for 57.1% higher than average price of previous purchases. This sale made a profit of USD 175,564 The average price that the ETF previously sold RVMD share for is USD 44.7829 so the ETF has sold 6131 shares on 2025-12-19 at a higher price than the previous selling average. |
| BNTX - BioNTech SE | SELL | -5,397 @ USD 92.5 | USD -499,223 | The ETF sold 5397 shares of BNTX on 2025-12-19. The shares were previously bought for an average price of USD 103.084. The BioNTech SE shares were sold for -10.3% lower than average price of previous purchases. This resulted in an overall loss of USD 57,122 The average price that the ETF previously sold BNTX share for is USD 103.63 which is higher than the selling price of USD 92.5 on 2025-12-19. |
| IONS - Ionis Pharmaceuticals Inc | SELL | -6,741 @ USD 79.57 | USD -536,381 | The ETF sold 6741 shares of IONS on 2025-12-19. The shares were previously bought for an average price of USD 56.8592. The Ionis Pharmaceuticals Inc shares were sold for 39.9% higher than average price of previous purchases. This sale made a profit of USD 153,094 The average price that the ETF previously sold IONS share for is USD 43.634 so the ETF has sold 6741 shares on 2025-12-19 at a higher price than the previous selling average. |
| MDGL - Madrigal Pharmaceuticals Inc | SELL | -911 @ USD 591.02 | USD -538,419 | The ETF sold 911 shares of MDGL on 2025-12-19. The shares were previously bought for an average price of USD 411.281. The Madrigal Pharmaceuticals Inc shares were sold for 43.7% higher than average price of previous purchases. This sale made a profit of USD 163,742 The average price that the ETF previously sold MDGL share for is USD 353.39 so the ETF has sold 911 shares on 2025-12-19 at a higher price than the previous selling average. |
| JAZZ - Jazz Pharmaceuticals PLC | SELL | -3,379 @ USD 166.99 | USD -564,259 | The ETF sold 3379 shares of JAZZ on 2025-12-19. The shares were previously bought for an average price of USD 135.407. The Jazz Pharmaceuticals PLC shares were sold for 23.3% higher than average price of previous purchases. This sale made a profit of USD 106,719 The average price that the ETF previously sold JAZZ share for is USD 126.033 so the ETF has sold 3379 shares on 2025-12-19 at a higher price than the previous selling average. |
| ASND - Ascendis Pharma AS | SELL | -2,981 @ USD 199.99 | USD -596,170 | The ETF sold 2981 shares of ASND on 2025-12-19. The shares were previously bought for an average price of USD 186.345. The Ascendis Pharma AS shares were sold for 7.3% higher than average price of previous purchases. This sale made a profit of USD 40,676 The average price that the ETF previously sold ASND share for is USD 159.626 so the ETF has sold 2981 shares on 2025-12-19 at a higher price than the previous selling average. |
| ARWR - Arrowhead Pharmaceuticals Inc | SELL | -9,063 @ USD 68.16 | USD -617,734 | The ETF sold 9063 shares of ARWR on 2025-12-19. The shares were previously bought for an average price of USD 30.2525. The Arrowhead Pharmaceuticals Inc shares were sold for 125.3% higher than average price of previous purchases. This sale made a profit of USD 343,556 The average price that the ETF previously sold ARWR share for is USD 22.9492 so the ETF has sold 9063 shares on 2025-12-19 at a higher price than the previous selling average. |
| ROIV - Roivant Sciences Ltd | SELL | -27,611 @ USD 22.41 | USD -618,763 | The ETF sold 27611 shares of ROIV on 2025-12-19. The shares were previously bought for an average price of USD 15.2175. The Roivant Sciences Ltd shares were sold for 47.3% higher than average price of previous purchases. This sale made a profit of USD 198,592 The average price that the ETF previously sold ROIV share for is USD 12.2775 so the ETF has sold 27611 shares on 2025-12-19 at a higher price than the previous selling average. |
| BMRN - Biomarin Pharmaceutical Inc | SELL | -10,505 @ USD 61.15 | USD -642,381 | The ETF sold 10505 shares of BMRN on 2025-12-19. The shares were previously bought for an average price of USD 57.0929. The Biomarin Pharmaceutical Inc shares were sold for 7.1% higher than average price of previous purchases. This sale made a profit of USD 42,620 The average price that the ETF previously sold BMRN share for is USD 61.208 which is higher than the selling price of USD 61.15 on 2025-12-19. |
| MRNA - Moderna Inc | SELL | -20,332 @ USD 33.8 | USD -687,222 | The ETF sold 20332 shares of MRNA on 2025-12-19. The shares were previously bought for an average price of USD 28.1569. The Moderna Inc shares were sold for 20.0% higher than average price of previous purchases. This sale made a profit of USD 114,736 The average price that the ETF previously sold MRNA share for is USD 33.1334 so the ETF has sold 20332 shares on 2025-12-19 at a higher price than the previous selling average. |
| EXEL - Exelixis Inc | SELL | -15,572 @ USD 44.3 | USD -689,840 | The ETF sold 15572 shares of EXEL on 2025-12-19. The shares were previously bought for an average price of USD 41.6794. The Exelixis Inc shares were sold for 6.3% higher than average price of previous purchases. This sale made a profit of USD 40,808 The average price that the ETF previously sold EXEL share for is USD 36.7872 so the ETF has sold 15572 shares on 2025-12-19 at a higher price than the previous selling average. |
| SMMT - Summit Therapeutics PLC | SELL | -40,317 @ USD 17.82 | USD -718,449 | The ETF sold 40317 shares of SMMT on 2025-12-19. The shares were previously bought for an average price of USD 20.4764. The Summit Therapeutics PLC shares were sold for -13.0% lower than average price of previous purchases. This resulted in an overall loss of USD 107,098 The average price that the ETF previously sold SMMT share for is USD 19.7768 which is higher than the selling price of USD 17.82 on 2025-12-19. |
| BBIO - BridgeBio Pharma Inc | SELL | -9,678 @ USD 76.3 | USD -738,431 | The ETF sold 9678 shares of BBIO on 2025-12-19. The shares were previously bought for an average price of USD 52.1831. The BridgeBio Pharma Inc shares were sold for 46.2% higher than average price of previous purchases. This sale made a profit of USD 233,403 The average price that the ETF previously sold BBIO share for is USD 37.16 so the ETF has sold 9678 shares on 2025-12-19 at a higher price than the previous selling average. |
| NBIX - Neurocrine Biosciences Inc | SELL | -5,123 @ USD 145 | USD -742,835 | The ETF sold 5123 shares of NBIX on 2025-12-19. The shares were previously bought for an average price of USD 135.725. The Neurocrine Biosciences Inc shares were sold for 6.8% higher than average price of previous purchases. This sale made a profit of USD 47,516 The average price that the ETF previously sold NBIX share for is USD 126.626 so the ETF has sold 5123 shares on 2025-12-19 at a higher price than the previous selling average. |
| SNY - Sanofi ADR | SELL | -17,606 @ USD 48.18 | USD -848,257 | The ETF sold 17606 shares of SNY on 2025-12-19. The shares were previously bought for an average price of USD 49.8689. The Sanofi ADR shares were sold for -3.4% lower than average price of previous purchases. This resulted in an overall loss of USD 29,735 The average price that the ETF previously sold SNY share for is USD 49.7776 which is higher than the selling price of USD 48.18 on 2025-12-19. |
| MEDP - Medpace Holdings Inc | SELL | -1,501 @ USD 568.36 | USD -853,108 | The ETF sold 1501 shares of MEDP on 2025-12-19. The shares were previously bought for an average price of USD 445.12. The Medpace Holdings Inc shares were sold for 27.7% higher than average price of previous purchases. This sale made a profit of USD 184,983 The average price that the ETF previously sold MEDP share for is USD 371.714 so the ETF has sold 1501 shares on 2025-12-19 at a higher price than the previous selling average. |
| VTRS - Viatris Inc | SELL | -71,641 @ USD 11.93 | USD -854,677 | The ETF sold 71641 shares of VTRS on 2025-12-19. The shares were previously bought for an average price of USD 9.92002. The Viatris Inc shares were sold for 20.3% higher than average price of previous purchases. This sale made a profit of USD 143,997 The average price that the ETF previously sold VTRS share for is USD 10.545 so the ETF has sold 71641 shares on 2025-12-19 at a higher price than the previous selling average. |
| INCY - Incyte Corporation | SELL | -10,040 @ USD 102.69 | USD -1,031,008 | The ETF sold 10040 shares of INCY on 2025-12-19. The shares were previously bought for an average price of USD 81.6071. The Incyte Corporation shares were sold for 25.8% higher than average price of previous purchases. This sale made a profit of USD 211,672 The average price that the ETF previously sold INCY share for is USD 73.3934 so the ETF has sold 10040 shares on 2025-12-19 at a higher price than the previous selling average. |
| RPRX - Royalty Pharma Plc | SELL | -27,264 @ USD 38.6 | USD -1,052,390 | The ETF sold 27264 shares of RPRX on 2025-12-19. The shares were previously bought for an average price of USD 36.708. The Royalty Pharma Plc shares were sold for 5.2% higher than average price of previous purchases. This sale made a profit of USD 51,583 The average price that the ETF previously sold RPRX share for is USD 30.5714 so the ETF has sold 27264 shares on 2025-12-19 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -9,082 @ USD 134.78 | USD -1,224,072 | The ETF sold 9082 shares of ILMN on 2025-12-19. The shares were previously bought for an average price of USD 105.819. The Illumina Inc shares were sold for 27.4% higher than average price of previous purchases. This sale made a profit of USD 263,024 The average price that the ETF previously sold ILMN share for is USD 107.383 so the ETF has sold 9082 shares on 2025-12-19 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -8,018 @ USD 174.8 | USD -1,401,546 | The ETF sold 8018 shares of BIIB on 2025-12-19. The shares were previously bought for an average price of USD 149.071. The Biogen Inc shares were sold for 17.3% higher than average price of previous purchases. This sale made a profit of USD 206,295 The average price that the ETF previously sold BIIB share for is USD 144.216 so the ETF has sold 8018 shares on 2025-12-19 at a higher price than the previous selling average. |
| INSM - Insmed Inc | SELL | -10,344 @ USD 174.84 | USD -1,808,545 | The ETF sold 10344 shares of INSM on 2025-12-19. The shares were previously bought for an average price of USD 141.595. The Insmed Inc shares were sold for 23.5% higher than average price of previous purchases. This sale made a profit of USD 343,886 The average price that the ETF previously sold INSM share for is USD 94.4042 so the ETF has sold 10344 shares on 2025-12-19 at a higher price than the previous selling average. |
| UTHR - United Therapeutics Corporation | SELL | -3,976 @ USD 517.13 | USD -2,056,109 | The ETF sold 3976 shares of UTHR on 2025-12-19. The shares were previously bought for an average price of USD 380.392. The United Therapeutics Corporation shares were sold for 35.9% higher than average price of previous purchases. This sale made a profit of USD 543,670 The average price that the ETF previously sold UTHR share for is USD 358.784 so the ETF has sold 3976 shares on 2025-12-19 at a higher price than the previous selling average. |
| ALNY - Alnylam Pharmaceuticals Inc | SELL | -5,714 @ USD 400.23 | USD -2,286,914 | The ETF sold 5714 shares of ALNY on 2025-12-19. The shares were previously bought for an average price of USD 395.411. The Alnylam Pharmaceuticals Inc shares were sold for 1.2% higher than average price of previous purchases. This sale made a profit of USD 27,536 The average price that the ETF previously sold ALNY share for is USD 284.419 so the ETF has sold 5714 shares on 2025-12-19 at a higher price than the previous selling average. |
| ARGX - argenx NV ADR | SELL | -2,716 @ USD 854.99 | USD -2,322,153 | The ETF sold 2716 shares of ARGX on 2025-12-19. The shares were previously bought for an average price of USD 715.907. The argenx NV ADR shares were sold for 19.4% higher than average price of previous purchases. This sale made a profit of USD 377,749 The average price that the ETF previously sold ARGX share for is USD 644.844 so the ETF has sold 2716 shares on 2025-12-19 at a higher price than the previous selling average. |
| REGN - Regeneron Pharmaceuticals Inc | SELL | -5,708 @ USD 767.96 | USD -4,383,516 | The ETF sold 5708 shares of REGN on 2025-12-19. The shares were previously bought for an average price of USD 649.194. The Regeneron Pharmaceuticals Inc shares were sold for 18.3% higher than average price of previous purchases. This sale made a profit of USD 677,916 The average price that the ETF previously sold REGN share for is USD 630.438 so the ETF has sold 5708 shares on 2025-12-19 at a higher price than the previous selling average. |